Navigation Links
Aethlon Medical Announces Washington, DC Shareholder Presentation
Date:12/20/2010

SAN DIEGO, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it will host a presentation for shareholders and other interested parties at 5:30 pm EST on January 12, 2011.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

The event will be held at the offices of Fabiani & Company located at 1100 Pennsylvania Avenue, NW, Suite 700, Washington, DC 20004, and is intended to provide investors with access to information presented by the company at the U.S. Department of Health and Human Services BARDA Industry Day in addition to the company's current business and future growth strategies.

As previously announced, the company was selected to present at this prestigious industry event.  Please see the company's press release dated December 14, 2010 for further information regarding this presentation.

As seating is limited, please contact Charlene Owen or John Salvador at:Charlene Owen858.459.7800 x 305cowen@aethlonmedical.comJohn P. SalvadorDirector, Communications & Investor Relations858.459.7800 x307jps@aethlonmedical.comAbout Aethlon MedicalAt Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.  However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union.  In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

  1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
  2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.  
  3. Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
  4. Bioterror and Pandemic Threats:  Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board
2. Aethlon Medical to Present at LD MICRO Conference on December 3, 2009
3. Aethlon Medical, Inc. Announces Annual Meeting Results
4. Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates
5. Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress
6. Medical science helps UK athletes reach peak performance
7. Rush-Copley Medical Center Selects Pharmacy Xpert from Thomson Reuters to Improve Medication Management
8. Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
9. Integrated Medical Systems Technology Recognized as Qualified Therapeutic Discovery
10. Wound Management Technologies to Present at LifeTech Capital Miami Medical Investors Conference
11. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Bermuda , Dec. 5, 2016 Axovant ... clinical-stage biopharmaceutical company focused on the treatment of dementia, ... intepirdine for the treatment of Alzheimer,s disease will be ... (CTAD) Meeting on Friday, December 9, 2016 in ... will show results of both simple and complex measures ...
(Date:12/5/2016)... COLORADO (PRWEB) , ... December 05, 2016 , ... ... series hosted by one of the nation’s premier cannabis technology and application experts, ... founder and CEO of Cultivate Colorado. Over the past 30 years, Chip Baker ...
(Date:12/5/2016)... SAN DIEGO , Dec. 5, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and other chronic ... is joining the company as Chief Financial Officer ... Renova Therapeutics with 20 years of experience in ... closely held biotech and software companies. Most recently, ...
(Date:12/5/2016)... , Dec. 5, 2016  Eisai Inc. ... open-label two-year study of rufinamide, which were presented ... Epilepsy Society (AES) held from December 2-6 in ... final two-year safety, tolerability and cognitive data showed ... experienced similar safety and tolerability profiles, cognitive development ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/2/2016)... December 1, 2016 The ... Voice), Future Technology (Iris Recognition System), Vehicle Type ... Global Forecast to 2021", published by MarketsandMarkets, the ... in 2016, and is projected to grow to ... of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a privately ... products for the objective detection of concussion and other ... has successfully completed a meeting with the U.S. Food ... blood test Pre-Submission Package. During the meeting company representatives ... as a precursor to commencement of a planned pilot ...
Breaking Biology News(10 mins):